Evidence map›Paper›PMID 41606180›Full record

ArticleScientific reports2026

Thyroid cancer detection and classification using spectral imaging and artificial intelligence.

Maya Almagor, Yotam Shapira, Adam Soker, Gabor Fischer, John Gartner, Sabine Mai, Yuval Garini

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Genomics and Multi-Omics to Guide Clinical Management in Thyroid Cancer.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maya Almagor *Biomedical Engineering Faculty & Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa, Israel.
Yotam Shapira *Biomedical Engineering Faculty & Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa, Israel. yotamshapira@campus.technion.ac.il.
Adam SokerBiomedical Engineering Faculty & Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa, Israel.
Gabor FischerDepartment of Pathology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
John GartnerDepartment of Pathology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
Sabine MaiDepartment of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Canada.
Yuval GariniBiomedical Engineering Faculty & Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa, Israel. yuval.garini@technion.ac.il.

Funding

Canada Research Chairs Program (CRCP) Tier 1Horizon 2020 HipMed 2022Israel Science Foundation 2019/17 and 2624/22Zimin Institute for AI Solutions in Healthcare 2024 Zimin 2024
6 · The paper itself

Abstract

Thyroid cancer is the most prevalent endocrine cancer, with a steadily rising incidence. Its diagnosis involves microscopic examination of tissue specimens, a process that can lead to misclassification with critical prognostic consequences. Numerous artificial intelligence techniques have been proposed for thyroid cancer detection, however, none have proven clinically relevant. We present an accurate diagnostic approach based on a newly developed spectral imaging system that rapidly measures the visible spectrum at each point on routinely prepared hematoxylin and eosin-stained tissue sections. These spectral images are analyzed with machine learning algorithms, classifying each nucleus while preserving interpretability for experts. The integration of spectral imaging and artificial intelligence enables precise, robust identification of normal and tumor cells, offering a straightforward, powerful approach for thyroid cancer assessment. By utilizing routinely stained tissue specimens and targeting specific pathological features, our method provides a tool to support pathologists, facilitating accurate and timely evaluations of thyroid cancer.

Indexed as

Artificial IntelligenceThyroid NeoplasmsAlgorithmsClassification AlgorithmsHumansIntelligent SystemsMachine Learning

Identifiers

PMID41606180
PMCPMC12909797

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.